It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Link To Story
It reads like a bad science fiction novel: A small Illinois biotech company cuts a deal with UCSD. The university agrees to test a substitute for human blood on comatose patients -- victims of gunshots and car crashes -- without the patients' consent. Within the city of San Diego, the experiment is targeted at several neighborhoods south of I-8, where many poor and minority residents are unlikely to have heard of the study and unlikelier still to have the resources to sue if something goes awry. The university conceals the identity of the city's paramedic units who carry the blood substitute. When a curious reporter asks for the names of the neighborhoods where the study is being carried out, a research coordinator working for the university tells him that the Chicago sponsor doesn't want the information made public because Wall Street moneymen -- hoping to reap a financial windfall from their investment in the company -- might sell if they discover the experiment is not going well. When the reporter asks university officials to provide details of two "adverse event" reports involving the study, the officials stonewall, saying the information is "nonpublic" because the university has signed a confidentiality agreement with the laboratory. But if Hollywood wouldn't buy that scenario, the University of California and the City of San Diego already have. A little more than two years ago, officials at UCSD signed an agreement with Northfield Laboratories for clinical trials of PolyHeme.
Gould held on, sacking the company's chief executive and eventually reaching an agreement in 2003 with the FDA to allow a new kind of clinical trial that could be run without getting the patient's consent. Employing a little-used exemption in FDA regulations, Gould proposed having paramedics in cities across America infuse PolyHeme into 360 patients. San Diego was one of those cities.
The City of San Diego moved forward with the trial in midsummer. In a memo dated August 10, 2004, the city's Emergency Medical Program manager, Donna Goldsmith, quietly informed the council that the PolyHeme trial would finally proceed. "Based upon previous trauma demographic data," the memo said, "it is projected that the San Diego region will contribute 40 patients to the study. The safety and efficacy of this artificial blood product have been demonstrated in several in-hospital studies involving more than 300 patients."
Particularly troubling to some observers are two in-house university reports of "adverse events" that have occurred.
A letter dated May 27, 2004, from Daniel Masys, M.D., then director of UCSD's Human Research Protections Program, to Hoyt discussed the first incident. "Your April 29, 2004 adverse event report for Project 030443 has been reviewed and accepted by the IRB Committee at the May 20, 2004 meeting," Masys wrote. The IRB, or Institutional Review Board, is a group set up by the university to review the ethics and integrity of research activities.
But according to records obtained from the City of San Diego, at the time the U-T story appeared, city officials and UCSD administrators were still negotiating when and where the city's paramedics would use PolyHeme.
Northfield Laboratories hopes to enlist 20 hospitals in the one-year study, which will enroll 720 patients. While the company hasn't publicly listed the hospitals that are taking part or considering participation, news reports have revealed that they include the Denver Health Medical Center; University of California at San Diego Medical Center; University of Texas Medical School in Houston; Loyola University Medical Center in Maywood, Illinois; Mayo Clinic in Rochester, Minnesota; and Regional Medical Center in Memphis.
In clinical trials to date, PolyHeme® has demonstrated no “clinically relevant” adverse effects. That is, they didn’t impact the patient’s safety or recovery.
Past studies have shown that PolyHeme® carries as much oxygen as blood, has not caused organ damage, keeps people alive who have lost all of their own blood, and can be infused up to two times a person’s entire blood volume.
irb.ucsd.edu...
Regulations established by the Federal government, (21 Code of Federal Regulations 50.24) specifies the conditions under which an exception from informed consent so that in emergency situations, research can be carried out even when consent is not possible because of the nature and extent of the patient’s injuries.
Patients are in a life-threatening situation, available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence is necessary to determine the safety and effectiveness of particular investigational interventions.
It is expected that patients will be unable to give informed consent because the extent of their injuries and the fact that they are in shock.
There won’t be time to find and ask for consent from the patient’s legally authorized representative (LAR) before beginning treatment.
The U.S. Food and Drug Administration (FDA) under regulations called 21 Code of Federal Regulations 50.24 specifies the conditions under which an exception from informed consent may be obtained. The Institutional Review Board (IRB) associated with each hospital approves its use locally.
irb.ucsd.edu...
Originally posted by FredT
This is what I said in an ATSNN article a while back on this subject
-------------------------------------------------------------------------
Synthetic Blood is one of the holy grails. Imagine blood that has a ultra long shelf life, can be preloaded with more than 4 molocules of oxygen and given to a hypoxic patient, Can be stored in large amounts and dropped easily into disaster zones.
In five human trials, PolyHeme has shown:
In clinical trials to date, PolyHeme® has demonstrated no “clinically relevant” adverse effects. That is, they didn’t impact the patient’s safety or recovery.
Past studies have shown that PolyHeme® carries as much oxygen as blood, has not caused organ damage, keeps people alive who have lost all of their own blood, and can be infused up to two times a person’s entire blood volume.
irb.ucsd.edu...
In regards to the consent issue:
Regulations established by the Federal government, (21 Code of Federal Regulations 50.24) specifies the conditions under which an exception from informed consent so that in emergency situations, research can be carried out even when consent is not possible because of the nature and extent of the patient’s injuries.
Patients are in a life-threatening situation, available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence is necessary to determine the safety and effectiveness of particular investigational interventions.
It is expected that patients will be unable to give informed consent because the extent of their injuries and the fact that they are in shock.
There won’t be time to find and ask for consent from the patient’s legally authorized representative (LAR) before beginning treatment.
The U.S. Food and Drug Administration (FDA) under regulations called 21 Code of Federal Regulations 50.24 specifies the conditions under which an exception from informed consent may be obtained. The Institutional Review Board (IRB) associated with each hospital approves its use locally.
irb.ucsd.edu...
Etc etc etc
Study of Blood Substitute for Trauma Patients Continues:
LEXINGTON, Ky. (May 23, 2006) – The University of Kentucky is continuing to take part in a national clinical research trial, along with 27 other trauma centers across the country, to evaluate the ability of an investigational blood substitute to reduce mortality among severely injured trauma patients......
Under the study's protocol, potential patients who do not wish to participate may opt out by obtaining a bracelet from study coordinators, similar to other medical alert identifiers.
Originally posted by Essedarius
While I do think the idea of something being used without a patient's consent is creepy, I think it's worth stopping a moment and really considering the situation....
I guess the question is: What exactly would you need to know about Polyheme that would raise it to the comfort level of popping antacids or getting a flu shot?
Originally posted by bsl4doc
I think the phrase "synthetic blood" is being misused a big here. They don't intend it to be a substitute for blood in a real, biological sense. They mean it in the same way saline could be labeled that. It's meant to keep your blood pressure and arterial volume up when you are losing a lot of blood. Polyheme just happens to contain a few important blood elements in addition to the salt water found in saline.
Mariella